5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one | 1914998-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
• 英文别名: pecavaptan；Pecavaptan；5-(4-chlorophenyl)-2-[[1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1,2,4-triazol-3-yl]methyl]-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-1,2,4-triazol-3-one
• CAS: 1914998-56-3
• 化学式: C₂₂H₁₉Cl₂F₃N₆O₃
• 分子量: 543.332
• InChiKey: AZXOTZCWQDJCLY-SJCJKPOMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-{3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}acetohydrazide 在 吡啶 、 sodium ethanolate 、 copper diacetate 作用下， 以 乙醇 、 2-甲基戊烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 、 5-(4-chlorophenyl)-2-({1-(3-chlorophenyl)-5-[(1R)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}-methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
  参考文献：
  名称：

  Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

  摘要：

  本发明涉及新颖的5-(羟基烷基)-1-苯基-1,2,4-三唑衍生物，以及制备此类化合物的方法、含有此类化合物的药物组合物，以及利用此类化合物或组合物治疗和/或预防疾病，特别是用于治疗和/或预防心血管和肾脏疾病。

  公开号：

  US20160122325A1

文献信息

• [EN] PROCESS FOR PREPARING 5-(ALKOXYCARBONYL)-AND 5-(CARBOXAMIDE)-1-ARYL-1,2,4-TRIAZOLE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS DE 5-(ALCOXYCARBONYLE)-ET DE 5- (CARBOXAMIDE)-1-ARYL-1,2,4-TRIAZOLE
  申请人：BAYER AG

  公开号：WO2021259852A1

  公开（公告）日：2021-12-30

  The present application relates to a novel and improved process for preparing 5- (alkoxycarbonyl)- and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives of the general formulas (III) and (IV), in which Ar1 represents a phenyl group, which is optionally substituted with one or more halogen atoms, R1 represents a (C1-C4)-alkyl group, which is optionally substituted with one or more substituents selected from a fluorine atom, hydroxy and oxo, R2 represents a (C1-C4)-alkoxycarbonyl group, and Ar2 represents a phenyl group or a 5- or 6-membered heteroaryl group attached via a ring carbon atom having one or two ring heteroatoms selected from a nitrogen atom and a sulfur atom, wherein any phenyl group and any 5- or 6- membered heteroaryl group are each optionally substituted, identically or differently, with one or two groups selected from a halogen atom, nitro, cyano, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylsulfanyl, (C1-C4)-alkoxycarbonyl, aminocarbonyl, -C(=O)N(H)CH3, - S(=O)2CH3, and -S(=O)2NH2, wherein said (C1-C4)-alkyl group, said (C1-C4)-alkoxy group and said (C1-C4)-alkylsulfanyl group are each optionally substituted with up to three fluorine atoms, and to novel precursors for preparation thereof.

  本申请涉及一种新型和改进的制备5-（烷氧羰基）-和5-（羧酰胺）-1-芳基-1,2,4-三唑衍生物的方法，其通式为（III）和（IV），其中Ar1代表一个苯基，可以用一个或多个卤素原子取代，R1代表一个（C1-C4）-烷基，可以用一个或多个从氟原子、羟基和氧代取代基中选择的取代基取代，R2代表一个（C1-C4）-烷氧羰基基团，Ar2代表一个苯基或通过一个环碳原子连接的一个五元或六元杂环基团，该环原子有一个或两个从氮原子和硫原子中选择的杂原子，其中任何苯基和任何五元或六元杂环基团可以相同或不同地用一个或两个从卤素原子、硝基、氰基、（C1-C4）-烷基、（C1-C4）-烷氧基、（C1-C4）-烷基硫基、（C1-C4）-烷氧羰基、氨基羰基、-C（=O）N（H）CH3、-S（=O）2 和-S（=O）2NH2中选择的基团取代，其中所述（C1-C4）-烷基，所述（C1-C4）-烷氧基和所述（C1-C4）-烷基硫基可以分别选择性地用最多三个氟原子取代，并且涉及用于制备它们的新型前体。
• COMBINATION OF FINERENONE AND PECAVAPTAN FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES
  申请人：Bayer AG

  公开号：EP3900722A1

  公开（公告）日：2021-10-27

  The present invention relates to pharmaceutical compositions and combinations comprising finerenone or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and pecavaptan, or a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof. The combination can be used for the treatment and/or prevention of cardiovascular and/or renal diseases in humans and other mammals.

  本发明涉及包含非格列酮、其水合物、溶液或药学上可接受的盐或其多晶型的药物组合物和山奈酚、其水合物、溶液或药学上可接受的盐或其多晶型的组合物。该组合可用于治疗和/或预防人类和其他哺乳动物的心血管和/或肾脏疾病。
• Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10703742B2

  公开（公告）日：2020-07-07

  The present application relates to a novel and improved process for preparing 5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole derivatives of the formula (I) in which R1A and R1B are independently selected from the group consisting of hydrogen, fluorine, chlorine, methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl, methoxy, difluoromethoxy and trifluoromethoxy, to novel precursors for preparation thereof, and to the preparation and use of the crystalline polymorph I of (5-(4-chlorophenyl)-2-(1-(3-chlorophenyl)-5-[(1S)-1-hydroxyethyl]-1H-1,2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one of the formula (I-A-1).

  本申请涉及一种新型改进工艺，用于制备式 (I) 的 5-（羟基烷基）-1-苯基-1,2,4-三唑衍生物 其中 R1A 和 R1B 分别独立地选自氢、氟、氯、甲基、一氟甲基、二氟甲基、三氟甲基、乙基、甲氧基、二氟甲氧基和三氟甲氧基组成的组、 以及制备和使用（5-(4-氯苯基)-2-(1-(3-氯苯基)-5-[(1S)-1-羟乙基]-1H-1、2,4-triazol-3-yl}methyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one of the formula (I-A-1).
• HYDROXYALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3215498B1

  公开（公告）日：2018-08-22
• VERFAHREN ZUR HERSTELLUNG VON 5-HYDROXYALKYL-SUBSTITUIERTEN 1-PHENYL-1,2,4-TRIAZOLDERIVATIVEN
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3452467A1

  公开（公告）日：2019-03-13